Considering an IT Investment For Your Clinical Diagnostics Lab? Help is Here

Next-generation sequencing data analysis management systems are the backbone of clinical diagnostics labs, providing vital functionality for day-to-day workings and business delivery. As a result, decisions about the tools to invest in can have far-reaching implications. 

Would it be best to improve, augment or entirely replace your existing systems? 

Which is the most resource intensive? 

Cost effective? 

Secure?

These aren’t the only questions.

Other considerations include scalability and future expansion potential, flexibility, and impacts on operations and turnaround time. 

It can be overwhelming. Luckily, we’re here to help, with two new guides to help you assess your current and future needs, and how to achieve them. 

Build vs. Buy: Six Questions to Consider When Investigating Clinical Diagnostics Informatics Solutions

Feeling like a victim of your own success? As testing demand increases, so does complexity, and IT issues that were once hidden are probably starting to surface. Experiencing unplanned downtime, difficulty deploying new pipelines, and challenges in finding and accessing data? These could bottleneck future growth.

Sounds like you need a reliable system that is prepared to grow alongside you. Custom-built Cloud solutions provide scalability, security, and lots of other benefits, which we outline in this Whitepaper. We’ll walk you through the decision-making process, and point out the advantages and disadvantages of the different IT solutions.

10 Tips to Scale Your Diagnostics Business & Grow Your Test Portfolio Globally

Ready to take your business to the next level? Great! If that involves expanding your footprint, either locally or globally, things could get complicated, especially when it comes to data sharing, storage and access. Are you prepared to navigate all the data sovereignty requirements and IP protection across locations? Do you know how to control access to pipeline algorithms and sensitive health data, and to comply with regionally-specific regulations?

By bringing all production pipelines into a single, unified cloud environment, with version-controlled pipeline updates rolled out simultaneously across your locales, you can effectively manage growth. This Whitepaper lays it all out, and explain why letting experts do the heavy lifting can pay dividends.

Still not convinced? Perhaps this handsome devil will help you decide:

Meet Us in Atlanta for AACR

We will be joining thousands of oncology researchers and clinicians this week at the American Association for Cancer Research Annual Meeting, March 29 – April 3 at the Georgia World Congress Center. Stop by our booth #3051 to learn how DNAnexus Apollo enables advanced exploration of cancer datasets for therapeutic target discovery. Our scientific experts will be onsite all week for demos and to answer all your bioinformatics questions.

Last year at AACR, in partnership with St. Jude Children’s Research Hospital and Microsoft, St. Jude Cloud was launched, the largest public repository of pediatric genomic cancer data. Offering a suite of unique analysis tools and visualizations, researchers can efficiently mine, analyze, and visualize next-generation sequencing data for pediatric cancer and other life threatening diseases to accelerate scientific discoveries.

This year, St. Jude Children’s Research Hospital is celebrating the one year anniversary of the St. Jude Cloud and since its inception, 10,000 WGS data have been analyzed in continuation of the search to find a cure for pediatric cancer and other life-threatening diseases. If you want to know more about the St. Jude Cloud, visit their booth #4136. We are excited to celebrate the one year anniversary with St. Jude Children’s Research Hospital and St. Jude Cloud team – how cool is it that we’re back at AACR together?!

Make sure to stop by either DNAnexus booth or the St. Jude Cloud booth, to celebrate with us at AACR! Check out our conference activities below. Can’t make it to any of our events? Request a meeting.

Demo: Explore Millions of Clinico-Genomic Data Points in Seconds with DNAnexus Apollo

  • Monday, April 1st – 1:00pm-2:00pm
  • Tuesday, April 2nd – 10:30am-11:30am

Cancer genomics is advancing precision medicine, leading to better diagnoses and treatment strategies. The Cancer Genome Atlas (TCGA), extensively characterized over 20,000 primary cancer and matched normal samples, creating a deep resource of over 25 petabytes of genomic, epigenomic, transcriptomic, and proteomic data. This landmark program has already lead to improvements in researchers’ ability to diagnose, treat and prevent cancer, yet mining this type of data for novel findings remains a huge endeavor.

DNAnexus Apollo enables at-scale navigation and exploration on combined genotypic and phenotypic data, whether it is TCGA data, your own protected data, or a combination. What actionable information will you find in your cancer datasets?

Customer Poster

3671 / 29 – Visualize 10,000 Whole Genomes from Pediatric Cancer Patients on St. Jude Cloud 

  • April 2nd, 1 – 5pm
  • Presenter: Clay McLeod, St Jude Children’s Research Hospital

Shaping the Future of Precision Medicine for Newborns

A Recap of Frontiers in Pediatric Genomic Medicine Conference

Rady Children’s Institute for Genomic Medicine’s (RCIGM) Frontiers in Pediatric Genomic Medicine Conference took place last week on the scenic shores of La Jolla, California. The third annual conference brought together innovators from children’s hospitals and genetics labs around the world who are making big strides in the field of pediatric genomics.  

The meeting began each day with a poignant patient story. Parents held their infant on stage while sharing the story of the very emotionally-trying start to their baby’s life. In all cases these babies were admitted to Rady’s NICU at less than one week old with unexplainable medical conditions linked to the nervous system. With no immediate diagnosis, the newborns’ bodies rapidly were shutting down, and in each case, the parents were told they would likely lose their baby.

With the parents consent, the newborns underwent rapid whole-genome sequencing (rWGS) to try and determine the cause of their symptoms. Leveraging Rady’s rWGS pipeline results were turned around in about a day. In each case, rWGS enabled the team at Rady’s to successfully identify a rare but treatable genetic disorder so the newborn could undergo targeted therapy to dramatically alter the course of the disease. The babies were able to be taken home from the NICU shortly after diagnosis, and are healthy and happy today.

Throughout the conference, other organizations shared their success stories of whole genome or exome sequencing for rapid diagnosis in newborns. Speakers also made a financial case for performing genomic sequencing on newborns, demonstrating that healthcare costs saved by a reduced length of hospitalization and ongoing care add up to more than the investment for sequencing. It is possible to save lives without increasing costs, a win-win for everyone.   

Hearing case study after case study of successful and rapid diagnosis with genomic sequencing in newborns drove home the message that the medical community is seeing concrete value in investing in rWGS. Further, as sequencing and bioinformatics technology continues to improve, physicians will have earlier access to genomic information to inform treatment decisions. As rWGS continues to gain momentum, genomic testing can become more universally available so newborns and their families can get the right diagnosis and the right treatment in time.